Abstract:DprE1 enzyme has emerged as one of the most vulnerable targets in M. tuberculosis and non‐covalent DprE1 inhibitors attracted considerable attention for the discovery of new anti‐tubercular agents. Among these compounds, TCA1, a non‐covalent DprE1 inhibitor has emerged as a potent drug candidate. In this regard, a series of TCA1 analogs were prepared through the pharmacophore hopping and evaluated for their anti‐tubercular activity against H37Ra. Among the compounds, Compounds 6 b and 6 f were emerged as lead compounds with MICs values of 4.0 and 8μg/mL respectively. Inhibitors of Decaprenylphosphoryl‐β‐D‐ribose 2′‐epimerase (DprE1) are being thoroughly explored as potential pharmacological entities for the development of new anti‐tubercular therapeutics. In this context, benzothiazole‐bearing compounds have emerged as potential non‐covalent DprE1 inhibitors active against mycobacterium tuberculosis. In view of the promising anti‐tubercular activity of benzothiazole based non‐covalent DprE1 inhibitor TCA1; a series of thirty small peptide conjugates of benzothiazole‐2‐carboxylic acid has been synthesized and evaluated for their anti‐tubercular activity against the M.tb H37Ra strain by broth microdilution assay. Among the compounds tested, compounds methyl (6‐methoxybenzo[d]thiazole‐2 carbonyl)tryptophylalaninate and methyl (6‐methylbenzo[d]thiazole‐2‐carbonyl)tryptophylalaninate demonstrated potential anti‐tubercular activity with minimum inhibitory concentration (MIC) values of 4 and 8 μg/mL, respectively. These compounds were further identified to be mycobactericidal and are completely killing the microbes at 8‐16 μg/mL concentrations. Furthermore, the cytotoxicity study of most potent compound methyl (6‐methoxybenzo[d]thiazole‐2 carbonyl)tryptophylalaninate illustrated no significant toxicity to the human cell line HepG2. Moreover, synthesised compounds were subject to molecular docking, ADME studies and MM‐GBSA calculations. In silico studies suggest that these compounds show strong interactions with key amino acids in the binding pocket of DprE1 (PDBID: 4KW5) with the most active conjugates residing well (with docking scores of −08.49 and −7.902 kcal/mol).

Identification of protein targets of compound HY-152E with anti-tuberculosis activity using drug affinity responsive target stability technique

Effects of a New Anti-Tuberculosis Compound,s28,on the Expression of Mycobacterium Tuberculosis Proteome

Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system

Target Prediction for an Open Access Set of Compounds Active Against Mycobacterium Tuberculosis

Identification of Novel Antimicrobial Compounds Targeting Mycobacterium tuberculosis S-Adenosyl-L-Homocysteine Hydrolase Using Dual Hierarchical In Silico Structure-Based Drug Screening

Identification of bioactive compounds Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening

Synthesis and Evaluation of (S,S)-N,N '-Bis-[3-(2,2 ',6,6 '-Tetramethylbenzhydryloxy)-2-hydroxy-propyl]-ethylenediamine (S2824) Analogs with Anti-Tuberculosis Activity

Suppressing Mycobacterium tuberculosis virulence and drug resistance by targeting Eis protein through computational drug discovery

Establishment and application of a high-throughput screening model targeting to shikimate dehydrogenase from Mycobacterium tuberculosis H37Rv

Protein Targets for Structure-Based Anti-Mycobacterium Tuberculosis Drug Discovery

Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B

Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment

Target-Directed Dynamic Combinatorial Chemistry Affords Binders of Mycobacterium Tuberculosis IspE

Copper transporter protein (MctB) as a therapeutic target to elicit antimycobacterial activity against tuberculosis

Cheminformatics-enhanced discovery of therapeutic agents targeting isocitrate lyase in Mycobacterium tuberculosis infections

Exploring optimal drug targets through subtractive proteomics analysis and pangenomic insights for tailored drug design in tuberculosis

In silico identification of phytochemical inhibitors for multidrug-resistant tuberculosis based on novel pharmacophore generation and molecular dynamics simulation studies

Characterization of a new leading compound against Mycobacterium Tuberculosis H37Ra in vitro

Bioinformatic Approaches Identify Hybrid Antibiotics against Tuberculosis via d-Amino Acid-Activating Adenylation Domains from Cordyceps militaris

Protein targets for structure-based anti- Mycobacterium tuberculosis drug discovery

Small Peptide Conjugates of Benzothiazole‐2‐Carboxylic Acids Targeting DprE1 Against Tuberculosis